Motion sickness drug linked to cases of robbery and assault – here's what you need to know about ‘devil's breath'
While most reports of devil's breath come from countries like Colombia, concerns about its use in Europe are not new. In 2015, three people were arrested in Paris for allegedly using the drug to rob victims, turning them into compliant 'zombies'.
The UK's first known murder linked to scopolamine was reported in 2019 when the Irish dancer Adrian Murphy was poisoned by thieves attempting to sell items stolen from him. In a more recent case in London, a woman reported symptoms consistent with scopolamine exposure after being targeted on public transport.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Scopolamine, also known as hycosine, is a tropane alkaloid, a type of plant-derived compound found in the nightshade family (Solanaceae). It has a long history: indigenous communities in South America traditionally used it for spiritual rituals due to its potent psychoactive effects.
In modern medicine, scopolamine (marketed in the UK as hyoscine hydrobromide) is prescribed to prevent motion sickness, nausea, vomiting and muscle spasms. It also reduces saliva production before surgery. Brand names include Kwells (tablets) and Scopoderm (patches).
As an anticholinergic drug, scopolamine blocks the neurotransmitter acetylcholine, which plays a vital role in memory, learning, and coordination. Blocking it helps reduce nausea by interrupting signals from the balance (vestibular) system to the brain. But it also comes with side effects, especially when used in high doses or outside a clinical setting.
Scopolamine disrupts the cholinergic system, which is central to memory formation and retrieval. As a result, it can cause temporary but severe memory loss: a key reason it's been weaponised in crimes. Some studies also suggest it increases oxidative stress in the brain, compounding its effects on cognition.
The drug's power to erase memory, sometimes described as 'zombifying', has made it a focus of forensic and criminal interest. Victims often describe confusion, hallucinations and a complete loss of control.
In clinical settings, scopolamine is sometimes used off-label for depression, excessive sweating, or even to help quit smoking. But outside these uses, it's increasingly associated with danger.
Recreational users are drawn to its hallucinogenic effects – but the line between tripping and toxic is razor thin.
In Colombia and other parts of South America, scopolamine, also known as burundanga, has been implicated in countless robberies and sexual assaults. Victims describe feeling dreamlike, compliant, and unable to resist or recall events. That's what makes it so sinister – it robs people of both agency and memory.
The drug is often administered surreptitiously. In its powdered form, it's odourless and tasteless, making it easy to slip into drinks or blow into someone's face, as some victims have reported. Online forums detail how to make teas or infusions from plant parts, seeds, roots, flowers – heightening the risk of DIY misuse.
Once ingested, the drug works quickly and exits the body within about 12 hours, making it hard to detect in routine drug screenings. For some people, even a dose under 10mg can be fatal.
Signs of scopolamine poisoning include rapid heartbeat and palpitations, dry mouth and flushed skin, blurred vision, confusion and disorientation, hallucinations and drowsiness.
If you experience any of these, especially after an unexpected drink or interaction, seek medical attention immediately.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
'Menopause made me forget my name'
"I didn't believe it could just be menopause. I thought it must be a brain tumour or dementia." Kirsty Dixon's life changed overnight when she started experiencing intense brain fog at 49 years old. Kirsty, from York, was staring at her screen at work one day, when suddenly she could not remember what she was doing. "I just asked myself 'What is my name?', and I couldn't even remember my own name. "I felt like I was going mad, I thought it was only me." The problems continued when she tried to access support. "I thought, why aren't people listening to me? "I've got something really serious going on but I can't get anyone to listen." Kirsty was told by a doctor that what she had experienced was part of the menopause. It is estimated that one in three women in the UK is going through the menopause at any given time. Kirsty, learning and development adviser at the University of York, is working to raise awareness of the lesser-known symptoms and the huge impact they can have on people's lives. "Before menopause I've always been a very bubbly person, very social, bit mischievous," she said. "Menopause came along and just put a big thunder cloud over my head. "I lost myself. The number of times my husband said 'I want my Kirsty back' while he was cuddling me and I was in floods of tears." Kirsty spent the next four years "fighting it" as she could not believe that those were menopause symptoms. Then, during lockdown, Kirsty found herself researching menopause for her work. She stumbled across an article by someone who had experienced the same symptoms as her. "I got that lightbulb moment that what I was experiencing was perfectly normal, I needed to understand it and know what I could do to help myself," she said. "I went from having this constant cloud and feeling useless, to actually owning my journey." Now aged 58, Kirsty runs two support groups for women experiencing the menopause, including a nature walking group around York, and a pop-up cafe in Acomb. They are non-profit and everyone is welcome, regardless of age or gender. She hopes the groups will encourage more people to talk about the lesser-known symptoms. "When you're going through it, it can feel so lonely," she said. "You feel like it's only you, and you think you're going mad. "One of the most important things I say to people is get your support network around you, and that's family, friends, and groups like this." Sarah Mortimer, 54, has been coming to the group since it started in 2022. She experienced an uncommon symptom of self-diagnosed burning mouth syndrome during her menopause, which involves developing blisters in the mouth with a burning feeling. "It can be really isolating, so to find groups like this is amazing," she said. "It makes a huge difference, knowing there's other people going through the same rubbish that you're going through. "It's that strength in numbers thing, and there's strength in the power of talking about the menopause." The group is based in York, but people travel from as far as Leeds, Sheffield and Beverley to attend. Kirsty says that it highlights an ongoing issue around the need for more support for people going through the menopause. "No one else was running a menopause cafe in York, so it was obviously something that was missing." She is calling for more groups like this so that people do not have to travel so far to get the support they need. "What I will say now, is as a post-menopausal woman, I am the most confident, the strongest, most creative person. "If someone said to me you can have your life again, without your menopause experience, actually, I'd say no, because it's what's made me the person I am today. "If I can get through that, I can get through anything." Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North or tell us a story you think we should be covering here. 'Fire service is helping me through the menopause' 'I mistook cancer signs for the menopause' What's the point of the menopause? NHS menopause advice
Yahoo
an hour ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.